购物车
您的购物车当前为空
JYQ-164 是⼀种针对⼈类的帕⾦森病蛋⽩ 7 (PARK7/DJ-1) ⼩分⼦抑制剂 (IC50=21 nM)。JYQ‑164 可通过共价且选择性地靶向 PARK7 蛋白的关键残基 Cys106 发挥抑制作用,对 PARK7 的抑制活性较已报道的抑制剂 JYQ‑88 提升约 5 倍,可用于帕金森病与癌症相关机制研究 。

JYQ-164 是⼀种针对⼈类的帕⾦森病蛋⽩ 7 (PARK7/DJ-1) ⼩分⼦抑制剂 (IC50=21 nM)。JYQ‑164 可通过共价且选择性地靶向 PARK7 蛋白的关键残基 Cys106 发挥抑制作用,对 PARK7 的抑制活性较已报道的抑制剂 JYQ‑88 提升约 5 倍,可用于帕金森病与癌症相关机制研究 。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,150 | 现货 |
| 产品描述 | JYQ-164 is a small‑molecule inhibitor targeting human Parkinson’s disease protein 7 (PARK7/DJ‑1) with an IC₅₀ value of 21 nM. It exerts its inhibitory effect by covalently and selectively targeting the key residue Cys106 of PARK7, and its inhibitory activity against PARK7 is approximately 5‑fold higher than that of the previously reported inhibitor JYQ‑88. JYQ-164 can be used in studies related to the mechanisms of Parkinson’s disease and cancer . |
| 靶点活性 | PARK7:21 nM |
| 分子量 | 530.62 |
| 分子式 | C23H26N6O5S2 |
| Smiles | O=C(NC1=NC2=C(CN(C(C3=CC(S(=O)(N4CCOCC4)=O)=CC=C3)=O)CC2)S1)[C@H]5CN(C#N)CC5 |
| 存储 | |||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 40.00 mg/mL (75.38 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多